Roy Herbst
Overview
Explore the profile of Roy Herbst including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
2666
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Sandler A, Graham C, Baggstrom M, Herbst R, Zergebel C, Saito K, et al.
J Thorac Oncol
. 2011 Jun;
6(8):1400-6.
PMID: 21673602
Introduction: S-1 is a rationally designed oral agent that combines the 5-fluorouracil prodrug tegafur with gimeracil and oteracil, which inhibit 5-fluorouracil degradation by dihydropyrimidine dehydronase and phosphorylation within the gastrointestinal...
22.
Zoog S, Ma C, Kaplan-Lefko P, Hawkins J, Moriguchi J, Zhou L, et al.
Cytometry A
. 2010 Jul;
77(9):849-60.
PMID: 20623688
Conatumumab is a monoclonal antibody specific for death receptor 5 (DR5) that activates caspases leading to DNA fragmentation and tumor-cell death. Like other Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) receptor...
23.
Haura E, Camidge D, Reckamp K, Chiappori A, Johnson F, Herbst R, et al.
J Thorac Oncol
. 2010 May;
5(6 Suppl 3):S207-13.
PMID: 20502275
The first Meeting on "Molecular Origins of Lung Cancer--Prospects for Personalized Prevention and Therapy" was held from January 10 to 14, 2010 in San Diego, California. The purpose of the...
24.
Zinner R, Novello S, Peng G, Herbst R, Obasaju C, Scagliotti G
Clin Lung Cancer
. 2010 Mar;
11(2):126-31.
PMID: 20199979
Introduction: Recent phase III studies in advanced non-small-cell lung cancer (NSCLC) have demonstrated differential efficacy for pemetrexed according to NSCLC histology. The results of 2 phase II studies of pemetrexed...
25.
Meuillet E, Zuohe S, Lemos R, Ihle N, Kingston J, Watkins R, et al.
Mol Cancer Ther
. 2010 Mar;
9(3):706-17.
PMID: 20197390
Phosphatidylinositol 3-kinase/phosphatidylinositide-dependent protein kinase 1 (PDPK1)/Akt signaling plays a critical role in activating proliferation and survival pathways within cancer cells. We report the molecular pharmacology and antitumor activity of PHT-427,...
26.
Camidge R, Gaspar L, Goss G, Kelly K, Ramalingam S, Reckamp K, et al.
J Thorac Oncol
. 2009 Jun;
4(7):930-5.
PMID: 19550249
Lung cancer is the leading cause of cancer-related death in the United States. Outcomes for patients with lung cancer have reached a plateau with cytotoxic chemotherapy. Lung cancer remains very...
27.
Salmon S, Chen H, Chen S, Herbst R, Tsao A, Tran H, et al.
J Thorac Oncol
. 2009 May;
4(6):689-96.
PMID: 19404214
Purpose: Although many lung cancers express the epidermal growth factor receptor and the vascular endothelial growth factor, only a small fraction of patients will respond to inhibitors of these pathways....
28.
Craft B, Kurzrock R, Lei X, Herbst R, Lippman S, Fu S, et al.
Cancer
. 2009 Jan;
115(8):1592-7.
PMID: 19165808
Phase 1 studies in cancer have changed in recent years. Now, with the advent of new, less toxic, targeted agents, more patients may be candidates for new drug studies earlier...
29.
Rice D, Swisher S, Pisters K, Fossella F, Herbst R, Hofstetter W, et al.
Chest
. 2008 Dec;
134(6):1349.
PMID: 19059972
No abstract available.
30.
Vokes E, Herbst R, Sandler A
Clin Adv Hematol Oncol
. 2006 Dec;
4(11 Suppl 23):1-10.
PMID: 17143257
Antiangiogenic therapy has emerged as an important concept in the treatment of solid tumors, including non-small cell lung cancer (NSCLC). Vascular endothelial growth factor (VEGF) represents an important therapeutic target,...